Focus Area Cancer Cell Therapy

The Client

  • Top 10 multinational Biopharma, historically a leading oncology player with a strong cash position and biologics-based clinical-regulatory and commercial infrastructure
  • Looking to understand how/where to be positioned within the rapidly evolving competitive IO landscape


  • Client missed the first IO wave (anti-PD1 mAbs), now seeking to ensure their current/future R&D and BD strategy is optimally aligned with emerging competitive and commercial opportunities in solid tumors
  • Lacking consensus needed to address looming oncology portfolio gap (early/mid-stage clinical candidates)


  • Provided a comprehensive and multifactorial assessment of the evolving scientific, clinical, competitive, regulatory, reimbursement, and commercial landscape
  • Individual discussions and multiple on-site workshops
  • Deep-dive on technical details and strategic implications for emerging modalities including ACT, bsAbs, and OVs

Valued Outcome

  • Provide recommendations on prioritization of in-house assets, ongoing partnerships, and external opportunities within attractive and feasible settings and platforms
  • Recommendations supported by extensive competitive and scientific analyses, CHBC expertise, and discussions with key client-company stakeholders